Skip to main content

Table 1 COI-studies in HF: Summary of main study characteristics

From: Cost-of-illness studies in heart failure: a systematic review 2004–2016

Reference

Country

Study size

Epidemiological approach

Method of Resource Quantification

Study period

Perspective

Study design

Mean age

Voigt 2014 [35]

USA

Prevalenta

Mixeda

2007–2012

Sa

R

Corrao 2014 [33]

Italy

26,949

Incident

Top-downa

2011

P

R

79

Czech 2013 [36]

Poland

Prevalenta

Mixeda

2009–2011

P

R

Delgado 2013 [37]

Spain

374

Prevalenta

Bottom-upa

2010

S

Pr

62

Dunlay 2011 [34]

USA

1054

Incidenta

Top-downa

1987–2006

Pa

R

76,8

Bogner 2010 [24]

USA

7996

Prevalenta

Bottom-upa

2000–2001

P

R

77,8–81,4

Zugck 2010 [30]

Germany

86,493

Prevalenta

Top-downa

2002

Pa

R

Neumann 2009 [29]

Germany

Prevalenta

Top-downa

2000–2007

Pa

R

Liao 2007 [23]

USA

4860

Prevalent

Top-down

1992–2003

Pa

Pr

75,6- 78,2

Liao 2006 [25]

USA

881

Mixed

Top-down

1992–1998

Pa

Pr

77,6- 81,6

Agvall 2005 [28]

Sweden

115

Prevalenta

Bottom-upa

1999–2000

Pa

R

77

Ory 2005 [26]

USA

17,835

Mixed

Bottom-upa

1999–2001

Pa

Pr

76,4

Stafylas 2016 [38]

Greece

307

Prevalent

Top-downa

2009–2011

P

Pr

66

Lee 2016 [31]

South Korea

475,019

Prevalent

Top-down

2014

P / S

R

Murphy 2016 [27]

Ireland

1292

Mixeda

Mixeda

2013

Pa

R

74,5

Ogah 2014 [32]

Nigeria

239

Prevalent

Mixeda

2009–2010

S

Pr

58

  1. anot clearly stated in the study, consensus by discussion
  2. S – societal; P – third-party payer; R – retrospective; Pr - prospective